Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics Initiates Human Abuse Liability Trial of CR845

GlobeNewswire July 31, 2014

Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan

GlobeNewswire July 16, 2014

Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer

GlobeNewswire June 24, 2014

Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug

PR Newswire June 20, 2014

Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain

GlobeNewswire June 18, 2014

Cara Therapeutics Names Eric J. Vandal Vice President, Commercial Operations

GlobeNewswire June 2, 2014

Cara Therapeutics Reports First Quarter 2014 Financial Results

GlobeNewswire May 12, 2014

Cara Therapeutics to Announce First Quarter 2014 Financial Results on May 12, 2014

GlobeNewswire May 5, 2014

Cara Therapeutics to Webcast Presentation at 13th Annual Needham Healthcare Conference

GlobeNewswire April 2, 2014

Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

GlobeNewswire March 27, 2014

Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014

GlobeNewswire March 20, 2014

Cara Therapeutics, Inc. [CARA] to Ring The NASDAQ Stock Market Opening Bell

GlobeNewswire March 10, 2014

Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Globe Newswire February 5, 2014

Cara Therapeutics Announces Pricing of Initial Public Offering

Globe Newswire January 31, 2014